Login Register Cart 0
Current Neuropharmacology

Current Neuropharmacology

Editor-in-Chief

ISSN (Print): 1570-159X
ISSN (Online): 1875-6190

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Neuropharmacological Interventions of Plant Origin for Parkinson's Disease: A Comprehensive Appraisal

Author(s): Umar Muzaffer, Bisma Gull, Zabeer Ahmed and Muzamil Ahmad*

Volume 23, Issue 14, 2025

Published on: 26 May, 2025

Page: [1816 - 1840] Pages: 25

DOI: 10.2174/1570159X23666250523112027

Price: $65

Become a Editorial Board Member
Become a Reviewer
Become a Editor
Become a Section Editor

Abstract

Parkinson's disease (PD) presents a complex challenge in neurodegenerative disorders, necessitating innovative therapeutic approaches. This review article elucidates the therapeutic potential of traditional herbal formulations alongside computational methods in PD research. Through comprehensive examination, we explore their mechanisms of action, synergistic effects, and implications for PD management. Furthermore, we discuss the significance of computational techniques such as molecular docking, molecular dynamics simulations, pharmacophore modeling, and network pharmacology. Our analysis underscores the integration of traditional wisdom with modern scientific inquiry, paving the way for nuanced interventions in PD.

Keywords: Parkinson's disease, neuropharmacology, geriatric psychiatry, ethnopharmacology, natural compounds, synergistic effects.

« Previous Next »

Graphical Abstract

Graphical abstract illustrating key findings of the study

[1]
Pellegrino, L.D.; Peters, M.E.; Lyketsos, C.G.; Marano, C.M. Depression in cognitive impairment. Curr. Psychiatry Rep., 2013, 15(9), 384.
[http://dx.doi.org/10.1007/s11920-013-0384-1] [PMID: 23933974]
[2]
Litwin, T.; Dusek, P.; Szafrański, T.; Dzieżyc, K.; Członkowska, A.; Rybakowski, J.K. Psychiatric manifestations in wilson’s disease: Possibilities and difficulties for treatment. Ther. Adv. Psychopharmacol., 2018, 8(7), 199-211.
[http://dx.doi.org/10.1177/2045125318759461] [PMID: 29977520]
[3]
Barth, R.; Gegusch, M. Functional neurological disorders - A Common but Often Unrecognized Diagnosis. Praxis (Bern), 2023, 112(5-6), 329-334.
[http://dx.doi.org/10.1024/1661-8157/a003997] [PMID: 37042404]
[4]
DeMaagd, G.; Philip, A. Parkinson’s disease and its management: Part 1: Disease entity, risk factors, pathophysiology, clinical presentation, and diagnosis. P&T, 2015, 40(8), 504-532.
[PMID: 26236139]
[5]
DeMaagd, G.; Philip, A. Parkinson’s disease and its management: Part 4: Treatment of motor complications. P&T, 2015, 40(11), 747-773.
[PMID: 26609209]
[6]
Giugni, J.C.; Okun, M.S. Treatment of advanced Parkinson’s disease. Curr. Opin. Neurol., 2014, 27(4), 450-460.
[http://dx.doi.org/10.1097/WCO.0000000000000118] [PMID: 24978634]
[7]
Witztum, E.; Margolin, J.; Levy, A. Misdiagnosis and labeling in psychiatry and their consequences: Part II. Harefuah, 1995, 129(1-2), 15-20, 79.
[PMID: 7557701]
[8]
Moeller, J.J.; Kurniawan, J.; Gubitz, G.J.; Ross, J.A.; Bhan, V. Diagnostic accuracy of neurological problems in the emergency department. Can. J. Neurol. Sci., 2008, 35(3), 335-341.
[http://dx.doi.org/10.1017/S0317167100008921] [PMID: 18714802]
[9]
Fujikawa, J.; Morigaki, R.; Yamamoto, N.; Oda, T.; Nakanishi, H.; Izumi, Y.; Takagi, Y. Therapeutic devices for motor symptoms in Parkinson’s disease: Current progress and a systematic review of recent randomized controlled trials. Front. Aging Neurosci., 2022, 14, 807909.
[http://dx.doi.org/10.3389/fnagi.2022.807909] [PMID: 35462692]
[10]
Magrinelli, F.; Picelli, A.; Tocco, P.; Federico, A.; Roncari, L.; Smania, N.; Zanette, G.; Tamburin, S. Pathophysiology of motor dysfunction in Parkinson’s disease as the rationale for drug treatment and rehabilitation. Parkinsons Dis., 2016, 2016, 1-18.
[http://dx.doi.org/10.1155/2016/9832839] [PMID: 27366343]
[11]
Bystritsky, A.; Khalsa, S.S.; Cameron, M.E.; Schiffman, J. Current diagnosis and treatment of anxiety disorders. P&T, 2013, 38(1), 30-57.
[PMID: 23599668]
[12]
Jena, B.N.; Kalra, S.; Yeravdekar, R. Emotional and psychological needs of people with diabetes. Indian J. Endocrinol. Metab., 2018, 22(5), 696-704.
[http://dx.doi.org/10.4103/ijem.IJEM_579_17] [PMID: 30294583]
[13]
Alexander, G.E. Biology of parkinson’s disease: Pathogenesis and pathophysiology of a multisystem neurodegenerative disorder. Dialogues Clin. Neurosci., 2004, 6(3), 259-280.
[http://dx.doi.org/10.31887/DCNS.2004.6.3/galexander] [PMID: 22033559]
[14]
Smith, Y.; Wichmann, T.; Factor, S.A.; DeLong, M.R. Parkinson’s disease therapeutics: New developments and challenges since the introduction of levodopa. Neuropsychopharmacology, 2012, 37(1), 213-246.
[http://dx.doi.org/10.1038/npp.2011.212] [PMID: 21956442]
[15]
Latif, S.; Jahangeer, M.; Maknoon Razia, D.; Ashiq, M.; Ghaffar, A.; Akram, M.; El Allam, A.; Bouyahya, A.; Garipova, L.; Ali Shariati, M.; Thiruvengadam, M.; Ansari, A.M. Dopamine in Parkinson’s disease. Clin. Chim. Acta, 2021, 522, 114-126.
[http://dx.doi.org/10.1016/j.cca.2021.08.009] [PMID: 34389279]
[16]
Lee, C.S.; Sauer, H.; Björklund, A. Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by intrastriatal 6-hydroxydopamine in the rat. Neuroscience, 1996, 72(3), 641-653.
[http://dx.doi.org/10.1016/0306-4522(95)00571-4] [PMID: 9157311]
[17]
Dias, V.; Junn, E.; Mouradian, M.M. The role of oxidative stress in Parkinson’s disease. J. Parkinsons Dis., 2013, 3(4), 461-491.
[http://dx.doi.org/10.3233/JPD-130230] [PMID: 24252804]
[18]
Meade, R.M.; Fairlie, D.P.; Mason, J.M. Alpha-synuclein structure and Parkinson’s disease – Lessons and emerging principles. Mol. Neurodegener., 2019, 14(1), 29.
[http://dx.doi.org/10.1186/s13024-019-0329-1] [PMID: 31331359]
[19]
Ozansoy, M.; Başak, A.N. The central theme of Parkinson’s disease: α-synuclein. Mol. Neurobiol., 2013, 47(2), 460-465.
[http://dx.doi.org/10.1007/s12035-012-8369-3] [PMID: 23180276]
[20]
Gómez-Benito, M.; Granado, N.; García-Sanz, P.; Michel, A.; Dumoulin, M.; Moratalla, R. Modeling Parkinson’s disease with the alpha-synuclein protein. Front. Pharmacol., 2020, 11, 356.
[http://dx.doi.org/10.3389/fphar.2020.00356] [PMID: 32390826]
[21]
Delenclos, M.; Burgess, J.D.; Lamprokostopoulou, A.; Outeiro, T.F.; Vekrellis, K.; McLean, P.J. Cellular models of alpha‐synuclein toxicity and aggregation. J. Neurochem., 2019, 150(5), 566-576.
[http://dx.doi.org/10.1111/jnc.14806] [PMID: 31265132]
[22]
Wong, Y.C.; Krainc, D. α-synuclein toxicity in neurodegeneration: Mechanism and therapeutic strategies. Nat. Med., 2017, 23(2), 1-13.
[http://dx.doi.org/10.1038/nm.4269] [PMID: 28170377]
[23]
Guo, C.; Sun, L.; Chen, X.; Zhang, D. Oxidative stress, mitochondrial damage and neurodegenerative diseases. Neural Regen. Res., 2013, 8(21), 2003-2014.
[http://dx.doi.org/10.3969/j.issn.1673-5374.2013.21.009] [PMID: 25206509]
[24]
Ge, P.; Dawson, V.L.; Dawson, T.M. PINK1 and Parkin mitochondrial quality control: A source of regional vulnerability in Parkinson’s disease. Mol. Neurodegener., 2020, 15(1), 20.
[http://dx.doi.org/10.1186/s13024-020-00367-7] [PMID: 32169097]
[25]
Isik, S.; Yeman Kiyak, B.; Akbayir, R.; Seyhali, R.; Arpaci, T. Microglia mediated neuroinflammation in Parkinson’s disease. Cells, 2023, 12(7), 1012.
[http://dx.doi.org/10.3390/cells12071012] [PMID: 37048085]
[26]
Mousa, A.; Bakhiet, M. Role of cytokine signaling during nervous system development. Int. J. Mol. Sci., 2013, 14(7), 13931-13957.
[http://dx.doi.org/10.3390/ijms140713931] [PMID: 23880850]
[27]
Singh, A.; Kukreti, R.; Saso, L.; Kukreti, S. Oxidative stress: A key modulator in neurodegenerative diseases. Molecules, 2019, 24(8), 1583.
[http://dx.doi.org/10.3390/molecules24081583] [PMID: 31013638]
[28]
Forloni, G. Alpha synuclein: Neurodegeneration and inflammation. Int. J. Mol. Sci., 2023, 24(6), 5914.
[http://dx.doi.org/10.3390/ijms24065914] [PMID: 36982988]
[29]
Gao, H.M.; Zhang, F.; Zhou, H.; Kam, W.; Wilson, B.; Hong, J.S. Neuroinflammation and α-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson’s disease. Environ. Health Perspect., 2011, 119(6), 807-814.
[http://dx.doi.org/10.1289/ehp.1003013] [PMID: 21245015]
[30]
Nuytemans, K.; Theuns, J.; Cruts, M.; Van Broeckhoven, C. Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: A mutation update. Hum. Mutat., 2010, 31(7), 763-780.
[http://dx.doi.org/10.1002/humu.21277] [PMID: 20506312]
[31]
Ball, N.; Teo, W.P.; Chandra, S.; Chapman, J. Parkinson’s disease and the environment. Front. Neurol., 2019, 10, 218.
[http://dx.doi.org/10.3389/fneur.2019.00218] [PMID: 30941085]
[32]
Kline, E.M.; Houser, M.C.; Herrick, M.K.; Seibler, P.; Klein, C.; West, A.; Tansey, M.G. Genetic and environmental factors in Parkinson’s disease converge on immune function and inflammation. Mov. Disord., 2021, 36(1), 25-36.
[http://dx.doi.org/10.1002/mds.28411] [PMID: 33314312]
[33]
Emamzadeh, F.N.; Surguchov, A. Parkinson’s disease: Biomarkers, treatment, and risk factors. Front. Neurosci., 2018, 12, 612.
[http://dx.doi.org/10.3389/fnins.2018.00612] [PMID: 30214392]
[34]
Höglinger, G.U.; Rizk, P.; Muriel, M.P.; Duyckaerts, C.; Oertel, W.H.; Caille, I.; Hirsch, E.C. Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nat. Neurosci., 2004, 7(7), 726-735.
[http://dx.doi.org/10.1038/nn1265] [PMID: 15195095]
[35]
Maiti, P.; Manna, J.; Dunbar, G.L. Current understanding of the molecular mechanisms in Parkinson’s disease: Targets for potential treatments. Transl. Neurodegener., 2017, 6(1), 28.
[http://dx.doi.org/10.1186/s40035-017-0099-z] [PMID: 29090092]
[36]
Stefanis, L. α-synuclein in Parkinson’s disease. Cold Spring Harb. Perspect. Med., 2012, 2(2), a009399.
[http://dx.doi.org/10.1101/cshperspect.a009399] [PMID: 22355802]
[37]
Vidović, M.; Rikalovic, M.G. Alpha-synuclein aggregation pathway in Parkinson’s disease: Current status and novel therapeutic approaches. Cells, 2022, 11(11), 1732.
[http://dx.doi.org/10.3390/cells11111732] [PMID: 35681426]
[38]
Codolo, G.; Plotegher, N.; Pozzobon, T.; Brucale, M.; Tessari, I.; Bubacco, L.; de Bernard, M. Triggering of inflammasome by aggregated α-synuclein, an inflammatory response in synucleinopathies. PLoS One, 2013, 8(1), e55375.
[http://dx.doi.org/10.1371/journal.pone.0055375] [PMID: 23383169]
[39]
Lema Tomé, C.M.; Tyson, T.; Rey, N.L.; Grathwohl, S.; Britschgi, M.; Brundin, P. Inflammation and α-synuclein’s prion-like behavior in Parkinson’s disease-is there a link? Mol. Neurobiol., 2013, 47(2), 561-574.
[http://dx.doi.org/10.1007/s12035-012-8267-8] [PMID: 22544647]
[40]
Stansley, B.; Yamamoto, B. L-dopa and brain serotonin system dysfunction. Toxics, 2015, 3(1), 75-88.
[http://dx.doi.org/10.3390/toxics3010075] [PMID: 29056652]
[41]
Haddad, F.; Sawalha, M.; Khawaja, Y.; Najjar, A.; Karaman, R. Dopamine and levodopa prodrugs for the treatment of parkinson’s disease. Molecules, 2017, 23(1), 40.
[http://dx.doi.org/10.3390/molecules23010040] [PMID: 29295587]
[42]
The international BNA 2023 festival of neuroscience. Brain Neurosci. Adv., 2023, 7.
[http://dx.doi.org/10.1177/23982128231180246]
[43]
Ammann, C.; Dileone, M.; Pagge, C.; Catanzaro, V.; Mata-Marín, D.; Hernández-Fernández, F.; Monje, M.H.G.; Sánchez-Ferro, Á.; Fernández-Rodríguez, B.; Gasca-Salas, C.; Máñez-Miró, J.U.; Martínez-Fernández, R.; Vela-Desojo, L.; Alonso-Frech, F.; Oliviero, A.; Obeso, J.A.; Foffani, G. Cortical disinhibition in Parkinson’s disease. Brain, 2020, 143(11), 3408-3421.
[http://dx.doi.org/10.1093/brain/awaa274] [PMID: 33141146]
[44]
Md, S.; Haque, S.; Sahni, J.K.; Baboota, S.; Ali, J. New non-oral drug delivery systems for Parkinson’s disease treatment. Expert Opin. Drug Deliv., 2011, 8(3), 359-374.
[http://dx.doi.org/10.1517/17425247.2011.556616] [PMID: 21314492]
[45]
Abstracts. Mov. Disord. Clin. Pract. (Hoboken), 2020, 7(S2), S6-S44.
[http://dx.doi.org/10.1002/mdc3.12923]
[46]
LeWitt, P.A.; Stocchi, F.; Arkadir, D.; Caraco, Y.; Adar, L.; Perlstein, I.; Case, R.; Giladi, N. The pharmacokinetics of continuous subcutaneous levodopa/carbidopa infusion: Findings from the ND0612 clinical development program. Front. Neurol., 2022, 13, 1036068.
[http://dx.doi.org/10.3389/fneur.2022.1036068] [PMID: 36438968]
[47]
Abbruzzese, G.; Barone, P.; Bonuccelli, U.; Lopiano, L.; Antonini, A. Continuous intestinal infusion of levodopa/carbidopa in advanced Parkinson’s disease: Efficacy, safety and patient selection. Funct. Neurol., 2012, 27(3), 147-154.
[PMID: 23402675]
[48]
DeMaagd, G.; Philip, A. Part 2: Introduction to the pharmacotherapy of Parkinson’s disease, with a focus on the use of dopaminergic agents. P&T, 2015, 40(9), 590-600.
[PMID: 26417179]
[49]
Ahlskog, J.E.; Maraganore, D.M.; Uitti, R.J.; Uhl, G.R. Brain imaging to assess the effects of dopamine agonists on progression of parkinson disease. JAMA, 2002, 288(3), 312.
[50]
Cavanagh, J.F.; Mueller, A.A.; Brown, D.R.; Janowich, J.R.; Story-Remer, J.H.; Wegele, A.; Richardson, S.P. Cognitive states influence dopamine-driven aberrant learning in Parkinson’s disease. Cortex, 2017, 90, 115-124.
[http://dx.doi.org/10.1016/j.cortex.2017.02.021] [PMID: 28384481]
[51]
Blanchet, P.J. Rationale for use of dopamine agonists in Parkinson’s disease: Review of ergot derivatives. Can. J. Neurol. Sci., 1999, 26(S2), S21-S26.
[http://dx.doi.org/10.1017/S0317167100000056] [PMID: 10451756]
[52]
De Vecchis, R.; Cantatrione, C.; Mazzei, D.; Baldi, C.; Di Maio, M. Non-Ergot dopamine agonists do not increase the risk of heart failure in Parkinson’s disease patients: A meta-analysis of randomized controlled trials. J. Clin. Med. Res., 2016, 8(6), 449-460.
[http://dx.doi.org/10.14740/jocmr2541e] [PMID: 27222673]
[53]
Wu, C.; Guo, H.; Xu, Y.; Li, L.; Li, X.; Tang, C.; Chen, D.; Zhu, M. The comparative efficacy of non-ergot dopamine agonist and potential risk factors for motor complications and side effects from NEDA use in early Parkinson’s disease: Evidence from clinical trials. Front. Aging Neurosci., 2022, 14, 831884.
[http://dx.doi.org/10.3389/fnagi.2022.831884] [PMID: 35527736]
[54]
Montastruc, J.L.; Rascol, O.; Senard, J.M. Current status of dopamine agonists in Parkinson’s disease management. Drugs, 1993, 46(3), 384-393.
[http://dx.doi.org/10.2165/00003495-199346030-00005] [PMID: 7693430]
[55]
Schiff, P.L., Jr Ergot and its alkaloids. Am. J. Pharm. Educ., 2006, 70(5), 98.
[http://dx.doi.org/10.1016/S0002-9459(24)07817-3] [PMID: 17149427]
[56]
Connolly, B.S.; Lang, A.E. Pharmacological treatment of Parkinson disease: A review. JAMA, 2014, 311(16), 1670-1683.
[http://dx.doi.org/10.1001/jama.2014.3654] [PMID: 24756517]
[57]
Juárez, O.H.; Calderón, G.D.; Hernández, G.E.; Barragán, M.G. The role of dopamine and its dysfunction as a consequence of oxidative stress. Oxid. Med. Cell. Longev., 2016, 2016(1), 9730467.
[http://dx.doi.org/10.1155/2016/9730467] [PMID: 26770661]
[58]
Mishra, A.; Singh, S.; Shukla, S. Physiological and functional basis of dopamine receptors and their role in neurogenesis: Possible implication for Parkinson’s disease. J. Exp. Neurosci., 2018, 12, 1179069518779829.
[http://dx.doi.org/10.1177/1179069518779829] [PMID: 29899667]
[59]
Kelley, B.J.; Duker, A.P.; Chiu, P. Dopamine agonists and pathologic behaviors. Parkinsons Dis., 2012, 2012, 1-5.
[http://dx.doi.org/10.1155/2012/603631] [PMID: 22567537]
[60]
Cawello, W.; Braun, M.; Boekens, H. Absorption, disposition, metabolic fate, and elimination of the dopamine agonist rotigotine in man: Administration by intravenous infusion or transdermal delivery. Drug Metab. Dispos., 2009, 37(10), 2055-2060.
[http://dx.doi.org/10.1124/dmd.109.027383] [PMID: 19608695]
[61]
Roth, J.; Ulmanová, O.; Růzicka, E. Organ changes induced by ergot derivative dopamine agonist drugs: Time to change treatment guidelines in Parkinson’s disease? Cas. Lek. Cesk., 2005, 144(2), 123-126.
[PMID: 15807300]
[62]
De Keyser, J.; De Backer, J.P.; Wilczak, N.; Herroelen, L. Dopamine agonists used in the treatment of Parkinson’s disease and their selectivity for the D1, D2, and D3 dopamine receptors in human striatum. Prog. Neuropsychopharmacol. Biol. Psychiatry, 1995, 19(7), 1147-1154.
[http://dx.doi.org/10.1016/0278-5846(95)00232-4] [PMID: 8787038]
[63]
Konta, B.; Frank, W. The treatment of Parkinson’s disease with dopamine agonists. GMS Health Technol. Assess., 2008, 4, Doc05.
[PMID: 21289911]
[64]
Kujawa, K.; Leurgans, S.; Raman, R.; Blasucci, L.; Goetz, C.G. Acute orthostatic hypotension when starting dopamine agonists in Parkinson’s disease. Arch. Neurol., 2000, 57(10), 1461-1463.
[http://dx.doi.org/10.1001/archneur.57.10.1461] [PMID: 11030798]
[65]
Figueroa, J.J.; Basford, J.R.; Low, P.A. Preventing and treating orthostatic hypotension: As easy as A, B, C. Cleve. Clin. J. Med., 2010, 77(5), 298-306.
[http://dx.doi.org/10.3949/ccjm.77a.09118] [PMID: 20439562]
[66]
Homann, C.N.; Wenzel, K.; Suppan, K.; Ivanic, G.; Kriechbaum, N.; Crevenna, R.; Ott, E. Sleep attacks in patients taking dopamine agonists: Review BMJ, 2002, 324(7352), 1483-1487.
[http://dx.doi.org/10.1136/bmj.324.7352.1483] [PMID: 12077032]
[67]
Cantor, C.R.; Stern, M.B. Dopamine agonists and sleep in Parkinson’s disease. Neurology, 2002, 58(4)(Suppl. 1), S71-S78.
[http://dx.doi.org/10.1212/WNL.58.suppl_1.S71] [PMID: 11909988]
[68]
Tan, Y.Y.; Jenner, P.; Chen, S.D. Monoamine Oxidase-B inhibitors for the treatment of Parkinson’s disease: Past, present, and future. J. Parkinsons Dis., 2022, 12(2), 477-493.
[http://dx.doi.org/10.3233/JPD-212976] [PMID: 34957948]
[69]
Finberg, J.P.M.; Rabey, J.M. Inhibitors of MAO-A and MAO-B in psychiatry and neurology. Front. Pharmacol., 2016, 7, 340.
[http://dx.doi.org/10.3389/fphar.2016.00340] [PMID: 27803666]
[70]
Alborghetti, M.; Nicoletti, F. Different generations of Type-B monoamine oxidase inhibitors in Parkinson’s disease: From bench to bedside. Curr. Neuropharmacol., 2019, 17(9), 861-873.
[http://dx.doi.org/10.2174/1570159X16666180830100754] [PMID: 30160213]
[71]
Leegwater-Kim, J.; Bortan, E. The role of rasagiline in the treatment of Parkinson’s disease. Clin. Interv. Aging, 2010, 5, 149-156.
[http://dx.doi.org/10.2147/CIA.S4145] [PMID: 20517484]
[72]
Lecht, S.; Haroutiunian, S.; Hoffman, A.; Lazarovici, P. Rasagiline - A novel MAO b inhibitor in Parkinson’s disease therapy. Ther. Clin. Risk Manag., 2007, 3(3), 467-474.
[PMID: 18488080]
[73]
Mhyre, T.R.; Boyd, J.T.; Hamill, R.W.; Maguire-Zeiss, K.A. Parkinson’s disease. Subcell. Biochem., 2012, 65, 389-455.
[http://dx.doi.org/10.1007/978-94-007-5416-4_16] [PMID: 23225012]
[74]
Goldman, J.G.; Litvan, I. Mild cognitive impairment in parkinson’s disease. Minerva Med., 2011, 102(6), 441-459.
[PMID: 22193376]
[75]
Litvan, I.; Goldman, J.G.; Tröster, A.I.; Schmand, B.A.; Weintraub, D.; Petersen, R.C.; Mollenhauer, B.; Adler, C.H.; Marder, K.; Williams-Gray, C.H.; Aarsland, D.; Kulisevsky, J.; Rodriguez-Oroz, M.C.; Burn, D.J.; Barker, R.A.; Emre, M. Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement disorder society task force guidelines. Mov. Disord., 2012, 27(3), 349-356.
[http://dx.doi.org/10.1002/mds.24893] [PMID: 22275317]
[76]
Aarsland, D.; Batzu, L.; Halliday, G.M.; Geurtsen, G.J.; Ballard, C.; Ray, C.K.; Weintraub, D. Parkinson disease-associated cognitive impairment. Nat. Rev. Dis. Primers, 2021, 7(1), 47.
[http://dx.doi.org/10.1038/s41572-021-00280-3] [PMID: 34210995]
[77]
Olivares, D.; Deshpande, V.K.; Shi, Y.; Lahiri, D.K.; Greig, N.H.; Rogers, J.T.; Huang, X. N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer’s disease, vascular dementia and Parkinson’s disease. Curr. Alzheimer Res., 2012, 9(6), 746-758.
[http://dx.doi.org/10.2174/156720512801322564] [PMID: 21875407]
[78]
Hauer, K.; Dutzi, I.; Gordt, K.; Schwenk, M. Specific motor and cognitive performances predict falls during ward-based geriatric rehabilitation in patients with dementia. Sensors (Basel), 2020, 20(18), 5385.
[http://dx.doi.org/10.3390/s20185385] [PMID: 32962248]
[79]
Sousa, N.M.F.; Macedo, R.C. Relationship between cognitive performance and mobility in patients with Parkinson’s disease: A cross-sectional study. Dement. Neuropsychol., 2019, 13(4), 403-409.
[http://dx.doi.org/10.1590/1980-57642018dn13-040006] [PMID: 31844493]
[80]
Prange, S.; Klinger, H.; Laurencin, C.; Danaila, T.; Thobois, S. Depression in patients with parkinson’s disease: Current understanding of its neurobiology and implications for treatment. Drugs Aging, 2022, 39(6), 417-439.
[http://dx.doi.org/10.1007/s40266-022-00942-1] [PMID: 35705848]
[81]
Marsh, L. Depression and parkinson’s disease: Current knowledge. Curr. Neurol. Neurosci. Rep., 2013, 13(12), 409.
[http://dx.doi.org/10.1007/s11910-013-0409-5] [PMID: 24190780]
[82]
Ślifirski, G.; Król, M.; Turło, J. 5-HT receptors and the development of new antidepressants. Int. J. Mol. Sci., 2021, 22(16), 9015.
[http://dx.doi.org/10.3390/ijms22169015] [PMID: 34445721]
[83]
Ferguson, J.M. SSRI antidepressant medications. Prim. Care Companion CNS Disord., 2001, 3(1), 22-27.
[http://dx.doi.org/10.4088/PCC.v03n0105] [PMID: 15014625]
[84]
Kano, O.; Ikeda, K.; Cridebring, D.; Takazawa, T.; Yoshii, Y.; Iwasaki, Y. Neurobiology of depression and anxiety in parkinson’s disease. Parkinsons Dis., 2011, 2011, 1-5.
[http://dx.doi.org/10.4061/2011/143547] [PMID: 21687804]
[85]
Briley, M.; Chantal, M. The importance of norepinephrine in depression. Neuropsychiatr. Dis. Treat., 2011, 7(Suppl. 1), 9-13.
[http://dx.doi.org/10.2147/NDT.S19619] [PMID: 21750623]
[86]
Heim, B.; Peball, M.; Krismer, F.; Djamshidian, A.; Seppi, K. Pimavanserin: A truly effective treatment for Parkinson’s disease psychosis? A review of interventions. Neuropsychiatr. Dis. Treat., 2023, 19, 1303-1312.
[http://dx.doi.org/10.2147/NDT.S371641] [PMID: 37274140]
[87]
Meltzer, H.Y.; Mills, R.; Revell, S.; Williams, H.; Johnson, A.; Bahr, D.; Friedman, J.H. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of Parkinson’s disease psychosis. Neuropsychopharmacology, 2010, 35(4), 881-892.
[http://dx.doi.org/10.1038/npp.2009.176] [PMID: 19907417]
[88]
Weil, R.; Reeves, S. Hallucinations in Parkinson’s disease: New insights into mechanisms and treatments. Adv. Clin. Neurosci. Rehabil., 2020, 19(4), 20-22.
[http://dx.doi.org/10.47795/ONNS5189] [PMID: 33102741]
[89]
Teeple, R.C.; Caplan, J.P.; Stern, T.A. Visual hallucinations. Prim. Care Companion J. Clin. Psychiatry, 2009, 11(1), 26-32.
[http://dx.doi.org/10.4088/PCC.08r00673] [PMID: 19333408]
[90]
Lee, H.M.; Koh, S.B. Many faces of Parkinson’s disease: Non-motor symptoms of Parkinson’s disease. J. Mov. Disord., 2015, 8(2), 92-97.
[http://dx.doi.org/10.14802/jmd.15003] [PMID: 26090081]
[91]
Fokunang, C.N.; Ndikum, V.; Tabi, O.Y.; Jiofack, R.B.; Ngameni, B.; Guedje, N.M.; Tembe-Fokunang, E.A.; Tomkins, P.; Barkwan, S.; Kechia, F.; Asongalem, E.; Ngoupayou, J.; Torimiro, N.J.; Gonsu, K.H.; Sielinou, V.; Ngadjui, B.T.; Angwafor, I.I.I., III; Nkongmeneck, A.; Abena, O.M.; Ngogang, J.; Asonganyi, T.; Colizzi, V.; Lohoue, J. Kamsu-Kom, Traditional medicine: Past, present and future research and development prospects and integration in the national health system of Cameroon. Afr. J. Tradit. Complement. Altern. Med., 2011, 8(3), 284-295.
[http://dx.doi.org/10.4314/ajtcam.v8i3.65276] [PMID: 22468007]
[92]
Yuan, H.; Ma, Q.; Ye, L.; Piao, G. The traditional medicine and modern medicine from natural products. Molecules, 2016, 21(5), 559.
[http://dx.doi.org/10.3390/molecules21050559] [PMID: 27136524]
[93]
Fabricant, D.S.; Farnsworth, N.R. The value of plants used in traditional medicine for drug discovery. Environ. Health Perspect., 2001, 109(Suppl. 1), 69-75.
[http://dx.doi.org/10.1289/ehp.01109s169]
[94]
Malík, M.; Tlustoš, P. Nootropic herbs, shrubs, and trees as potential cognitive enhancers. Plants, 2023, 12(6), 1364.
[http://dx.doi.org/10.3390/plants12061364] [PMID: 36987052]
[95]
Kennedy, D.O.; Wightman, E.L. Herbal extracts and phytochemicals: Plant secondary metabolites and the enhancement of human brain function. Adv. Nutr., 2011, 2(1), 32-50.
[http://dx.doi.org/10.3945/an.110.000117] [PMID: 22211188]
[96]
Lampariello, L.R.; Cortelazzo, A.; Guerranti, R.; Sticozzi, C.; Valacchi, G. The magic velvet bean of mucuna pruriens. J. Tradit. Complement. Med., 2012, 2(4), 331-339.
[http://dx.doi.org/10.1016/S2225-4110(16)30119-5] [PMID: 24716148]
[97]
Katzenschlager, R.; Evans, A.; Manson, A.; Patsalos, P.N.; Ratnaraj, N.; Watt, H.; Timmermann, L.; Van der Giessen, R.; Lees, A.J. Mucuna pruriens in Parkinson’s disease: A double blind clinical and pharmacological study. J. Neurol. Neurosurg. Psychiatry, 2004, 75(12), 1672-1677.
[http://dx.doi.org/10.1136/jnnp.2003.028761] [PMID: 15548480]
[98]
Cole, G.M.; Teter, B.; Frautschy, S.A. Neuroprotective effects of curcumin. Adv. Exp. Med. Biol., 2007, 595, 197-212.
[http://dx.doi.org/10.1007/978-0-387-46401-5_8] [PMID: 17569212]
[99]
Mishra, S.; Palanivelu, K. The effect of curcumin (turmeric) on Alzheimer′s disease: An overview. Ann. Indian Acad. Neurol., 2008, 11(1), 13-19.
[http://dx.doi.org/10.4103/0972-2327.40220] [PMID: 19966973]
[100]
Van Norman, G.A. Limitations of animal studies for predicting toxicity in clinical trials: Is it time to rethink our current approach. JACC Basic Transl. Sci., 2019, 4(7), 845-854.
[http://dx.doi.org/10.1016/j.jacbts.2019.10.008] [PMID: 31998852]
[101]
Van Norman, G.A. Limitations of animal studies for predicting toxicity in clinical trials: Part 2: Potential alternatives to the use of animals in preclinical trials. JACC Basic Transl. Sci., 2020, 5(4), 387-397.
[http://dx.doi.org/10.1016/j.jacbts.2020.03.010] [PMID: 32363250]
[102]
Pirintsos, S.; Panagiotopoulos, A.; Bariotakis, M.; Daskalakis, V.; Lionis, C.; Sourvinos, G.; Karakasiliotis, I.; Kampa, M.; Castanas, E. From traditional ethnopharmacology to modern natural drug discovery: A methodology discussion and specific examples. Molecules, 2022, 27(13), 4060.
[http://dx.doi.org/10.3390/molecules27134060] [PMID: 35807306]
[103]
Nebrisi, E.E. Neuroprotective activities of curcumin in Parkinson’s disease: A review of the literature. Int. J. Mol. Sci., 2021, 22(20), 11248.
[http://dx.doi.org/10.3390/ijms222011248] [PMID: 34681908]
[104]
Sharifi-Rad, J.; Rayess, Y.E.; Rizk, A.A.; Sadaka, C.; Zgheib, R.; Zam, W.; Sestito, S.; Rapposelli, S.; Neffe-Skocińska, K.; Zielińska, D.; Salehi, B.; Setzer, W.N.; Dosoky, N.S.; Taheri, Y.; El Beyrouthy, M.; Martorell, M.; Ostrander, E.A.; Suleria, H.A.R.; Cho, W.C.; Maroyi, A.; Martins, N. Turmeric and its major compound curcumin on health: bioactive effects and safety profiles for food, pharmaceutical, biotechnological and medicinal applications. Front. Pharmacol., 2020, 11, 01021.
[http://dx.doi.org/10.3389/fphar.2020.01021] [PMID: 33041781]
[105]
Hwang, O. Role of oxidative stress in Parkinson’s disease. Exp. Neurobiol., 2013, 22(1), 11-17.
[http://dx.doi.org/10.5607/en.2013.22.1.11] [PMID: 23585717]
[106]
Singh, P.K.; Kotia, V.; Ghosh, D.; Mohite, G.M.; Kumar, A.; Maji, S.K. Curcumin modulates α-synuclein aggregation and toxicity. ACS Chem. Neurosci., 2013, 4(3), 393-407.
[http://dx.doi.org/10.1021/cn3001203] [PMID: 23509976]
[107]
Ahmad, B.; Lapidus, L.J. Curcumin prevents aggregation in α-synuclein by increasing reconfiguration rate. J. Biol. Chem., 2012, 287(12), 9193-9199.
[http://dx.doi.org/10.1074/jbc.M111.325548] [PMID: 22267729]
[108]
Gehm, B.D.; McAndrews, J.M.; Chien, P.Y.; Jameson, J.L. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc. Natl. Acad. Sci. USA, 1997, 94(25), 14138-14143.
[http://dx.doi.org/10.1073/pnas.94.25.14138] [PMID: 9391166]
[109]
Buljeta, I.; Pichler, A.; Šimunović, J.; Kopjar, M. Beneficial effects of red wine polyphenols on human health: Comprehensive review. Curr. Issues Mol. Biol., 2023, 45(2), 782-798.
[http://dx.doi.org/10.3390/cimb45020052] [PMID: 36825997]
[110]
Ungurianu, A.; Zanfirescu, A.; Margină, D. Regulation of gene expression through food—curcumin as a sirtuin activity modulator. Plants, 2022, 11(13), 1741.
[http://dx.doi.org/10.3390/plants11131741] [PMID: 35807694]
[111]
Lagouge, M.; Argmann, C.; Gerhart-Hines, Z.; Meziane, H.; Lerin, C.; Daussin, F.; Messadeq, N.; Milne, J.; Lambert, P.; Elliott, P.; Geny, B.; Laakso, M.; Puigserver, P.; Auwerx, J. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell, 2006, 127(6), 1109-1122.
[http://dx.doi.org/10.1016/j.cell.2006.11.013] [PMID: 17112576]
[112]
Meng, T.; Xiao, D.; Muhammed, A.; Deng, J.; Chen, L.; He, J. Anti-inflammatory action and mechanisms of resveratrol. Molecules, 2021, 26(1), 229.
[http://dx.doi.org/10.3390/molecules26010229] [PMID: 33466247]
[113]
Gomes, B.A.Q.; Silva, J.P.B.; Romeiro, C.F.R.; dos Santos, S.M.; Rodrigues, C.A.; Gonçalves, P.R.; Sakai, J.T.; Mendes, P.F.S.; Varela, E.L.P.; Monteiro, M.C. Neuroprotective mechanisms of resveratrol in Alzheimer’s disease: Role of SIRT1. Oxid. Med. Cell. Longev., 2018, 2018(1), 8152373.
[http://dx.doi.org/10.1155/2018/8152373] [PMID: 30510627]
[114]
Price, N.L.; Gomes, A.P.; Ling, A.J.Y.; Duarte, F.V.; Martin-Montalvo, A.; North, B.J.; Agarwal, B.; Ye, L.; Ramadori, G.; Teodoro, J.S.; Hubbard, B.P.; Varela, A.T.; Davis, J.G.; Varamini, B.; Hafner, A.; Moaddel, R.; Rolo, A.P.; Coppari, R.; Palmeira, C.M.; de Cabo, R.; Baur, J.A.; Sinclair, D.A. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab., 2012, 15(5), 675-690.
[http://dx.doi.org/10.1016/j.cmet.2012.04.003] [PMID: 22560220]
[115]
Zhou, J.; Yang, Z.; Shen, R.; Zhong, W.; Zheng, H.; Chen, Z.; Tang, J.; Zhu, J. Resveratrol improves mitochondrial biogenesis function and activates PGC-1α pathway in a preclinical model of early brain injury following subarachnoid hemorrhage. Front. Mol. Biosci., 2021, 8, 620683.
[http://dx.doi.org/10.3389/fmolb.2021.620683] [PMID: 33968980]
[116]
Minocha, T.; Birla, H.; Obaid, A.A.; Rai, V.; Sushma, P.; Shivamallu, C.; Moustafa, M.; Al-Shehri, M.; Al-Emam, A.; Tikhonova, M.A.; Yadav, S.K.; Poeggeler, B.; Singh, D.; Singh, S.K. Flavonoids as promising neuroprotectants and their therapeutic potential against Alzheimer’s disease. Oxid. Med. Cell. Longev., 2022, 2022, 1-13.
[http://dx.doi.org/10.1155/2022/6038996] [PMID: 36071869]
[117]
Panche, A.N.; Diwan, A.D.; Chandra, S.R. Flavonoids: An overview. J. Nutr. Sci., 2016, 5, e47-e47.
[http://dx.doi.org/10.1017/jns.2016.41] [PMID: 28620474]
[118]
Vauzour, D.; Vafeiadou, K.; Rodriguez-Mateos, A.; Rendeiro, C.; Spencer, J.P.E. The neuroprotective potential of flavonoids: A multiplicity of effects. Genes Nutr., 2008, 3(3-4), 115-126.
[http://dx.doi.org/10.1007/s12263-008-0091-4] [PMID: 18937002]
[119]
Bellavite, P. Neuroprotective potentials of flavonoids: Experimental studies and mechanisms of action. Antioxidants, 2023, 12(2), 280.
[http://dx.doi.org/10.3390/antiox12020280] [PMID: 36829840]
[120]
Pizzino, G.; Irrera, N.; Cucinotta, M.; Pallio, G.; Mannino, F.; Arcoraci, V.; Squadrito, F.; Altavilla, D.; Bitto, A. Oxidative stress: Harms and benefits for human health. Oxid. Med. Cell. Longev., 2017, 2017(1), 8416763.
[http://dx.doi.org/10.1155/2017/8416763] [PMID: 28819546]
[121]
Miyamoto, N.; Izumi, H.; Miyamoto, R.; Kondo, H.; Tawara, A.; Sasaguri, Y.; Kohno, K. Quercetin induces the expression of peroxiredoxins 3 and 5 via the Nrf2/NRF1 transcription pathway. Invest. Ophthalmol. Vis. Sci., 2011, 52(2), 1055-1063.
[http://dx.doi.org/10.1167/iovs.10-5777] [PMID: 21051700]
[122]
Sharma, A.; Parikh, M.; Shah, H.; Gandhi, T. Modulation of Nrf2 by quercetin in doxorubicin-treated rats. Heliyon, 2020, 6(4), e03803.
[http://dx.doi.org/10.1016/j.heliyon.2020.e03803] [PMID: 32337383]
[123]
Singh, N.A.; Mandal, A.K.A.; Khan, Z.A. Potential neuroprotective properties of epigallocatechin-3-gallate (EGCG). Nutr. J., 2015, 15(1), 60.
[http://dx.doi.org/10.1186/s12937-016-0179-4] [PMID: 27268025]
[124]
Chen, B.; Zhang, W.; Lin, C.; Zhang, L. A comprehensive review on beneficial effects of catechins on secondary mitochondrial diseases. Int. J. Mol. Sci., 2022, 23(19), 11569.
[http://dx.doi.org/10.3390/ijms231911569] [PMID: 36232871]
[125]
Ayaz, M.; Sadiq, A.; Junaid, M.; Ullah, F.; Ovais, M.; Ullah, I.; Ahmed, J.; Shahid, M. Flavonoids as prospective neuroprotectants and their therapeutic propensity in aging associated neurological disorders. Front. Aging Neurosci., 2019, 11, 155.
[http://dx.doi.org/10.3389/fnagi.2019.00155] [PMID: 31293414]
[126]
Jansen, R.L.M.; Brogan, B.; Whitworth, A.J.; Okello, E.J. Effects of five ayurvedic herbs on locomotor behaviour in a drosophila melanogaster Parkinson’s disease model. Phytother. Res., 2014, 28(12), 1789-1795.
[http://dx.doi.org/10.1002/ptr.5199] [PMID: 25091506]
[127]
Singh, B.; Pandey, S.; Verma, R.; Ansari, J.A.; Mahdi, A.A. Comparative evaluation of extract of Bacopa monnieri and Mucuna pruriens as neuroprotectant in MPTP model of Parkinson’s disease. Indian J. Exp. Biol., 2016, 54(11), 758-766.
[PMID: 30179419]
[128]
Pathania, R.; Chawla, P.; Khan, H.; Kaushik, R.; Khan, M. A. An assessment of potential nutritive and medicinal properties of mucuna pruriens: A natural food legume. 3 Biotech, 2020, 10(6), 261.
[http://dx.doi.org/10.1007/s13205-020-02253-x]
[129]
Galani, V.J.; Rana, D.G. Dopamine mediated antidepressant effect of mucuna pruriens seeds in various experimental models of depression. Ayu, 2014, 35(1), 90-97.
[http://dx.doi.org/10.4103/0974-8520.141949] [PMID: 25364207]
[130]
Kamkaen, N.; Chittasupho, C.; Vorarat, S.; Tadtong, S.; Phrompittayarat, W.; Okonogi, S.; Kwankhao, P. Mucuna pruriens seed aqueous extract improved neuroprotective and acetylcholinesterase inhibitory effects compared with synthetic l-dopa. Molecules, 2022, 27(10), 3131.
[http://dx.doi.org/10.3390/molecules27103131] [PMID: 35630617]
[131]
Hadjiconstantinou, M.; Neff, N.H. Enhancing aromatic l-amino acid decarboxylase activity: Implications for L-DOPA treatment in Parkinson’s disease. CNS Neurosci. Ther., 2008, 14(4), 340-351.
[http://dx.doi.org/10.1111/j.1755-5949.2008.00058.x] [PMID: 19040557]
[132]
Hegde, M.; Girisa, S.; Bharathwaj, C.B.; Vishwa, R.; Kunnumakkara, A.B. Curcumin formulations for better bioavailability: What we learned from clinical trials thus far? ACS Omega, 2023, 8(12), 10713-10746.
[http://dx.doi.org/10.1021/acsomega.2c07326] [PMID: 37008131]
[133]
Weeks, B.S. Formulations of dietary supplements and herbal extracts for relaxation and anxiolytic action. Relarian. Med. Sci. Monit., 2009, 15(11), RA256-RA262.
[PMID: 19865069]
[134]
Aguiar, S.; Borowski, T. Neuropharmacological review of the nootropic herb Bacopa monnieri. Rejuvenation Res., 2013, 16(4), 313-326.
[http://dx.doi.org/10.1089/rej.2013.1431] [PMID: 23772955]
[135]
Krause, D.L.; Müller, N. Neuroinflammation, microglia and implications for anti-inflammatory treatment in Alzheimer’s disease. Int. J. Alzheimers Dis., 2010, 2010, 1-9.
[http://dx.doi.org/10.4061/2010/732806] [PMID: 20798769]
[136]
Lu, P.; Jones, L.L.; Snyder, E.Y.; Tuszynski, M.H. Neural stem cells constitutively secrete neurotrophic factors and promote extensive host axonal growth after spinal cord injury. Exp. Neurol., 2003, 181(2), 115-129.
[http://dx.doi.org/10.1016/S0014-4886(03)00037-2] [PMID: 12781986]
[137]
El Ouaamari, Y.; Van den Bos, J.; Willekens, B.; Cools, N.; Wens, I. Neurotrophic factors as regenerative therapy for neurodegenerative diseases: Current status, challenges and future perspectives. Int. J. Mol. Sci., 2023, 24(4), 3866.
[http://dx.doi.org/10.3390/ijms24043866] [PMID: 36835277]
[138]
Tansey, M.G.; McCoy, M.K.; Frank-Cannon, T.C. Neuroinflammatory mechanisms in Parkinson’s disease: Potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp. Neurol., 2007, 208(1), 1-25.
[http://dx.doi.org/10.1016/j.expneurol.2007.07.004] [PMID: 17720159]
[139]
Fatima, U.; Roy, S.; Ahmad, S.; Ali, S.; Elkady, W.M.; Khan, I.; Alsaffar, R.M.; Adnan, M.; Islam, A.; Hassan, M.I. Pharmacological attributes of Bacopa monnieri extract: Current updates and clinical manifestation. Front. Nutr., 2022, 9, 972379.
[http://dx.doi.org/10.3389/fnut.2022.972379] [PMID: 36061899]
[140]
Li, F.S.; Weng, J.K. Demystifying traditional herbal medicine with modern approach. Nat. Plants, 2017, 3(8), 17109.
[http://dx.doi.org/10.1038/nplants.2017.109] [PMID: 28758992]
[141]
Yuan, H.; Ma, Q.; Cui, H.; Liu, G.; Zhao, X.; Li, W.; Piao, G. How can synergism of traditional medicines benefit from network pharmacology? Molecules, 2017, 22(7), 1135.
[http://dx.doi.org/10.3390/molecules22071135] [PMID: 28686181]
[142]
Leena, M.M.; Silvia, M.G.; Vinitha, K.; Moses, J.A.; Anandharamakrishnan, C. Synergistic potential of nutraceuticals: Mechanisms and prospects for futuristic medicine. Food Funct., 2020, 11(11), 9317-9337.
[http://dx.doi.org/10.1039/D0FO02041A] [PMID: 33211054]
[143]
Lehár, J.; Krueger, A.S.; Avery, W.; Heilbut, A.M.; Johansen, L.M.; Price, E.R.; Rickles, R.J.; Short, G.F., III; Staunton, J.E.; Jin, X.; Lee, M.S.; Zimmermann, G.R.; Borisy, A.A. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat. Biotechnol., 2009, 27(7), 659-666.
[http://dx.doi.org/10.1038/nbt.1549] [PMID: 19581876]
[144]
Reale, M.; Costantini, E.; Jarlapoodi, S.; Serra, F.; Aielli, L.; Khan, H.; Belwal, T.; Falasca, K. Neuroprotective potential of bacopa monnieri: Modulation of inflammatory signals. CNS Neurol. Disord. Drug Targets, 2023, 22(3), 441-451.
[http://dx.doi.org/10.2174/1871527321666220111124047] [PMID: 35021981]
[145]
Weiner, B.J.; Lewis, M.A.; Clauser, S.B.; Stitzenberg, K.B. In search of synergy: Strategies for combining interventions at multiple levels. J. Natl. Cancer Inst. Monogr., 2012, 2012(44), 34-41.
[http://dx.doi.org/10.1093/jncimonographs/lgs001] [PMID: 22623594]
[146]
Lewis, M.A.; Fitzgerald, T.M.; Zulkiewicz, B.; Peinado, S.; Williams, P.A. Identifying synergies in multilevel interventions. Health Educ. Behav., 2017, 44(2), 236-244.
[http://dx.doi.org/10.1177/1090198116673994] [PMID: 28330388]
[147]
Yang, Y.; Zhang, Z.; Li, S.; Ye, X.; Li, X.; He, K. Synergy effects of herb extracts: Pharmacokinetics and pharmacodynamic basis. Fitoterapia, 2014, 92, 133-147.
[http://dx.doi.org/10.1016/j.fitote.2013.10.010] [PMID: 24177191]
[148]
Williamson, E. Synergy and other interactions in phytomedicines. Phytomedicine, 2001, 8(5), 401-409.
[http://dx.doi.org/10.1078/0944-7113-00060] [PMID: 11695885]
[149]
Mukherjee, P.K.; Venkatesh, P.; Ponnusankar, S. Ethnopharmacology and integrative medicine - Let the history tell the future. J. Ayurveda Integr. Med., 2010, 1(2), 100-109.
[http://dx.doi.org/10.4103/0975-9476.65077] [PMID: 21836796]
[150]
Reyes-García, V. The relevance of traditional knowledge systems for ethnopharmacological research: Theoretical and methodological contributions. J. Ethnobiol. Ethnomed., 2010, 6(1), 32.
[http://dx.doi.org/10.1186/1746-4269-6-32] [PMID: 21083913]
[151]
Sheng-Ji, P. Ethnobotanical approaches of traditional medicine studies: Some experiences from Asia. Pharm. Biol., 2001, 39(Suppl. 1), 74-79.
[http://dx.doi.org/10.1076/phbi.39.s1.74.0005] [PMID: 21554174]
[152]
Aziz, M.A.; Khan, A.H.; Adnan, M.; Ullah, H. Traditional uses of medicinal plants used by Indigenous communities for veterinary practices at Bajaur Agency, Pakistan. J. Ethnobiol. Ethnomed., 2018, 14(1), 11.
[http://dx.doi.org/10.1186/s13002-018-0212-0] [PMID: 29378636]
[153]
Demie, G.; Negash, M.; Awas, T. Ethnobotanical study of medicinal plants used by indigenous people in and around Dirre Sheikh Hussein heritage site of South-eastern Ethiopia. J. Ethnopharmacol., 2018, 220, 87-93.
[http://dx.doi.org/10.1016/j.jep.2018.03.033] [PMID: 29601979]
[154]
Cloud, Q.Y.; Redvers, N. Honoring indigenous sacred places and spirit in environmental health. Environ. Health Insights, 2023, 17, 11786302231157507.
[http://dx.doi.org/10.1177/11786302231157507] [PMID: 36825244]
[155]
Fitzpatrick, E.F.M.; Martiniuk, A.L.C.; D’Antoine, H.; Oscar, J.; Carter, M.; Elliott, E.J. Seeking consent for research with indigenous communities: A systematic review. BMC Med. Ethics, 2016, 17(1), 65.
[http://dx.doi.org/10.1186/s12910-016-0139-8] [PMID: 27770780]
[156]
Moore, N.; Hamza, N.; Berke, B.; Umar, A. News from Tartary: An ethnopharmacological approach to drug and therapeutic discovery. Br. J. Clin. Pharmacol., 2017, 83(1), 33-37.
[http://dx.doi.org/10.1111/bcp.13042] [PMID: 27297624]
[157]
Iglesias-Lopez, C.; Agustí, A.; Vallano, A.; Obach, M. Current landscape of clinical development and approval of advanced therapies. Mol. Ther. Methods Clin. Dev., 2021, 23, 606-618.
[http://dx.doi.org/10.1016/j.omtm.2021.11.003] [PMID: 34901306]
[158]
Imran, Y.; Wijekoon, N.; Gonawala, L.; Chiang, Y.C.; De Silva, K.R.D. Biopiracy: Abolish corporate hijacking of indigenous medicinal entities. Sci. World J., 2021, 2021, 1-8.
[http://dx.doi.org/10.1155/2021/8898842] [PMID: 33679261]
[159]
Steel, A.; Foley, H.; Bugarcic, A.; Wardle, J.; Boyd, H.; Breakspear, I.; Carlton, A-L.; Cope, G.; Dua, K.; Greenway, P. Exploring criteria for the translation of traditional knowledge within contemporary clinical practice, research, policy, and education: A stakeholder forum. J. Integr. Complement. Med., 2023, 29(6-7), 348-360.
[http://dx.doi.org/10.1089/jicm.2022.0683]
[160]
Duty, S.; Jenner, P. Animal models of Parkinson’s disease: A source of novel treatments and clues to the cause of the disease. Br. J. Pharmacol., 2011, 164(4), 1357-1391.
[http://dx.doi.org/10.1111/j.1476-5381.2011.01426.x] [PMID: 21486284]
[161]
Pienaar, I.S.; Götz, J.; Feany, M.B. Parkinson’s disease: Insights from non-traditional model organisms. Prog. Neurobiol., 2010, 92(4), 558-571.
[http://dx.doi.org/10.1016/j.pneurobio.2010.09.001] [PMID: 20851733]
[162]
Schober, A. Classic toxin-induced animal models of Parkinson’s disease: 6-OHDA and MPTP. Cell Tissue Res., 2004, 318(1), 215-224.
[http://dx.doi.org/10.1007/s00441-004-0938-y] [PMID: 15503155]
[163]
Umscheid, C.A.; Margolis, D.J.; Grossman, C.E. Key concepts of clinical trials: A narrative review. Postgrad. Med., 2011, 123(5), 194-204.
[http://dx.doi.org/10.3810/pgm.2011.09.2475] [PMID: 21904102]
[164]
Wong, C.H.; Siah, K.W.; Lo, A.W. Estimation of clinical trial success rates and related parameters. Biostatistics, 2019, 20(2), 273-286.
[http://dx.doi.org/10.1093/biostatistics/kxx069] [PMID: 29394327]
[165]
Gupta, U.; Verma, M. Placebo in clinical trials. Perspect. Clin. Res., 2013, 4(1), 49-52.
[http://dx.doi.org/10.4103/2229-3485.106383] [PMID: 23533982]
[166]
Evans, K.; Colloca, L.; Pecina, M.; Katz, N. What can be done to control the placebo response in clinical trials? A narrative review. Contemp. Clin. Trials, 2021, 107, 106503.
[http://dx.doi.org/10.1016/j.cct.2021.106503] [PMID: 34237458]

Rights & Permissions Print Cite
Article Metrics
Pdf icon 33
Html icon 2
Find your institution